276 related articles for article (PubMed ID: 1800666)
1. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
Kleyweg RP; van der Meché FG
J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):957-60. PubMed ID: 1800666
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
Visser LH; van der Meché FG; Meulstee J; van Doorn PA
J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
[TBL] [Abstract][Full Text] [Related]
4. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA
Ther Apher; 1997 May; 1(2):129-30. PubMed ID: 10225757
[TBL] [Abstract][Full Text] [Related]
5. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome.
Bril V; Ilse WK; Pearce R; Dhanani A; Sutton D; Kong K
Neurology; 1996 Jan; 46(1):100-3. PubMed ID: 8559353
[TBL] [Abstract][Full Text] [Related]
6. Second response to immunoglobulin in recurrent Guillain-Barré syndrome.
Nagappan R; Barker J
N Z Med J; 1998 Nov; 111(1077):433-4. PubMed ID: 9861925
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.
Visser LH; Schmitz PI; Meulstee J; van Doorn PA; van der Meché FG
Neurology; 1999 Aug; 53(3):598-604. PubMed ID: 10449126
[TBL] [Abstract][Full Text] [Related]
8. [A case of Guillain-Barré syndrome treated with plasma exchange and intravenous high-dose immune globulin].
Imai N; Miyata K; Terayama Y; Ishihara N
Rinsho Shinkeigaku; 1997 Jun; 37(6):520-2. PubMed ID: 9366182
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.
van der Meché FG; Schmitz PI
N Engl J Med; 1992 Apr; 326(17):1123-9. PubMed ID: 1552913
[TBL] [Abstract][Full Text] [Related]
10. [Value of intravenous immunoglobulins. A case of Guillain-Barré syndrome].
Hidou M; Olivier J; Vivant JF
Rev Neurol (Paris); 1992; 148(11):706-8. PubMed ID: 1303562
[TBL] [Abstract][Full Text] [Related]
11. High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome.
Ravasio A; Pasquinelli M; Currò Dossi B; Neri W; Guidi C; Gessaroli M; Rasi F; Fabbri R; Mazzini G; Rebucci GG
Ital J Neurol Sci; 1995 Oct; 16(7):487-92. PubMed ID: 8749707
[TBL] [Abstract][Full Text] [Related]
12. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin versus plasma exchange in Guillain-Barré syndrome.
Ng KK; Howard RS; Hirsch NP; Miller DH
Neurology; 1993 Dec; 43(12):2729; author reply 2730-1. PubMed ID: 8255495
[No Abstract] [Full Text] [Related]
14. [Respective indications of plasma exchange and high-dose immunoglobulins in polyradiculoneuritis and myasthenia gravis].
Raphaël JC; Annane D; Chevret S; Chillet P; Gajdos P
Presse Med; 1996 Oct; 25(31):1516-22. PubMed ID: 8958883
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome.
Kleyweg RP; van der Meché FG; Schmitz PI
Transfus Sci; 1994 Dec; 15(4):389-92. PubMed ID: 10172508
[No Abstract] [Full Text] [Related]
16. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin.
Haupt WF; Rosenow F; van der Ven C; Borberg H; Pawlik G
J Neurol Sci; 1996 May; 137(2):145-9. PubMed ID: 8782169
[TBL] [Abstract][Full Text] [Related]
17. The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously?
van der Meché FG
Ann Med Interne (Paris); 1994; 145(5):293-5. PubMed ID: 7985934
[No Abstract] [Full Text] [Related]
18. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome.
Rees JH
J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):148-9. PubMed ID: 9489520
[No Abstract] [Full Text] [Related]
19. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange.
Romano JG; Rotta FT; Potter P; Rosenfeld V; Santibanez R; Rocha B; Bradley WG
Muscle Nerve; 1998 Oct; 21(10):1327-30. PubMed ID: 9736064
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2010 Jun; (6):CD002063. PubMed ID: 20556755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
